Fulcrum Therapeutics (FULC) Total Non-Current Liabilities: 2019-2025
Historic Total Non-Current Liabilities for Fulcrum Therapeutics (FULC) over the last 6 years, with Sep 2025 value amounting to $16.3 million.
- Fulcrum Therapeutics' Total Non-Current Liabilities fell 24.28% to $16.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.3 million, marking a year-over-year decrease of 24.28%. This contributed to the annual value of $17.5 million for FY2024, which is 21.60% down from last year.
- According to the latest figures from Q3 2025, Fulcrum Therapeutics' Total Non-Current Liabilities is $16.3 million, which was up 14.25% from $14.3 million recorded in Q2 2025.
- In the past 5 years, Fulcrum Therapeutics' Total Non-Current Liabilities registered a high of $34.3 million during Q2 2022, and its lowest value of $14.0 million during Q1 2025.
- In the last 3 years, Fulcrum Therapeutics' Total Non-Current Liabilities had a median value of $20.3 million in 2024 and averaged $19.7 million.
- Data for Fulcrum Therapeutics' Total Non-Current Liabilities shows a maximum YoY decreased of 29.63% (in 2025) over the last 5 years.
- Quarterly analysis of 4 years shows Fulcrum Therapeutics' Total Non-Current Liabilities stood at $27.5 million in 2022, then declined by 19.03% to $22.3 million in 2023, then fell by 21.60% to $17.5 million in 2024, then declined by 24.28% to $16.3 million in 2025.
- Its last three reported values are $16.3 million in Q3 2025, $14.3 million for Q2 2025, and $14.0 million during Q1 2025.